The effect of @entity228 on metalloproteinase levels of XXXX .

@entity1 @entity1476 @entity228 @entity2843 @entity1495 @entity1412
OBJECTIVES: The aim of this study was to investigate the effect of @entity228 treatment on topical and systemic metalloproteinase levels of @entity1 with @entity1412 ( @entity1412 ). STUDY DESIGN: Prospective clinical trial. METHODS: The study included @entity1 undergoing a paranasal sinus operation due to @entity1412 . Oral @entity228 therapy was performed on all @entity1 before endoscopic sinus surgery. Endoscopic and radiological evaluation were performed and nasal tissue specimens and venous blood samples were collected before (preop phase) and after @entity228 treatment (periop phase) and also one month after surgery (postop phase). Endoscopic and computed tomography scan findings were scored adequately and all tissue and blood samples were examined cumulatively. RESULTS: The study included 27 @entity1 with inflammatory @entity1412 . Preop tissue @entity1476 ( @entity1476 ) levels were found to be significantly lower than preop and postop concentrations. In contrast, periop serum @entity1476 levels were found to be significantly higher than preop and postop concentrations. Periop @entity2843 ( @entity2843 ) levels were also found to be significantly lower than preop and postop concentrations, similar to @entity1476 tissue concentrations. However, there was no statistical difference among tissue @entity1495 concentrations of the three phases. In addition, there was also no statistical difference among serum @entity1495 levels of the three phases. CONCLUSIONS: Oral @entity228 treatment especially reduces tissue @entity1476 , then @entity2843 . Severity of @entity1412 primarily correlates with increasing tissue @entity1476 / @entity2843 ratio, then @entity1495 / @entity2843 . These results suggest that selective inhibition for @entity1476 and activation for @entity2843 might be a novel therapeutic strategy for @entity1 with @entity1412 .
